证券代码：002298 证券简称：中电鑫龙 编号：2025-054 安徽中电鑫龙科技股份有限公司（以下简称"公司"或"本公司"）2025 年第二次独立董事专门会议于 2025 年 8 月 27 日以通讯方式召开。本次会议应出 席独立董事 3 人，实际出席独立董事 3 人，全体独立董事共同推举许礼进先生召 集并主持本次会议。本次独立董事专门会议的召集、召开及表决程序符合《公司 法》、《公司章程》、《独立董事制度》、《独立董事专门会议制度》等有关规 定。 安徽中电鑫龙科技股份有限公司 二○二五年八月二十七日 经审查，全体独立董事认为：本次变更公司员工持股计划部分条款的事项符 合《公司法》《证券法》《关于上市公司实施员工持股计划试点的指导意见》《深 圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》等相关 法律、法规、规范性文件有关规定，已取得了现阶段必要的批准与授权，并履行 了相应的审议程序，符合《试点指导意见》《自律监管指引第 1 号》等有关法 律、法规和规范性文件的规定，不存在损害公司及全体股东利益的情形。因此， 我们同意《关于变更公司员工持股计划部分条款的议案》，并同意提交公司第十 届董事会 ...

Meeting Overview - The third meeting of the 10th Supervisory Board of Anhui Zhongdian Xinlong Technology Co., Ltd. was held on August 27, 2025, with all three supervisors present, complying with the Company Law and Articles of Association [1][2] Resolutions Passed - The Supervisory Board unanimously approved the 2025 Half-Year Report and its summary, confirming that the report accurately reflects the company's actual situation without any false records or misleading statements [1] - The Supervisory Board approved the amendment of certain terms of the employee stock ownership plan, stating that the changes have received necessary approvals and do not harm the interests of the company or its shareholders, nor will they adversely affect the company's strategic development or financial status [2]

Investment Rating - The report maintains an "Outperform the Market" rating for the company [5][16][20]. Core Views - The company's revenue decreased slightly, with a transition from profit to loss. In H1 2025, the company achieved revenue of 1.295 billion yuan, a year-on-year decline of 8.23%. The net profit attributable to the parent company was -50.5 million yuan, a decrease of 96 million yuan year-on-year, aligning with market expectations [1][3][7]. - The decline in revenue is primarily attributed to the slower-than-expected conversion of new contracts. The gross profit margin fell by 4.11 percentage points to 40.33% [1][3][7]. - The company has 14 ongoing PPP projects, and new regulations from the Ministry of Finance are expected to improve cash flow and reduce impairment burdens [2][12][15]. - The company plans to repurchase shares worth 100-150 million yuan at a price not exceeding 29.5 yuan per share, which is seen as a positive signal for shareholder confidence [2][12][15]. Financial Performance Summary - For H1 2025, the company reported a revenue of 1.295 billion yuan, down 8.23% year-on-year. The revenue from Puyue Technology was 482 million yuan, a decline of 5.9%, accounting for 37% of total revenue [1][7]. - The gross profit margin for the instrument, software, and consumables segment was 44.55%, down 3.77 percentage points year-on-year. The operating service, testing service, and consulting service segment saw a revenue of 213 million yuan, down 11.83%, with a gross profit margin of 35.77%, down 4.03 percentage points [2][12]. - The company expects net profits for 2025-2027 to be 267 million, 344 million, and 415 million yuan, respectively, with year-on-year growth rates of 29.2%, 28.8%, and 20.6% [3][16]. Segment Performance - The revenue from the instrument, related software, and consumables business was 896 million yuan, down 7.39% year-on-year. The environmental equipment and engineering business generated 135 million yuan, down 2.3% [2][12]. Shareholder Confidence - The planned share repurchase is intended to boost shareholder confidence and is indicative of management's positive outlook on the company's future [2][12][15].

Core Points - Chengdu Xian Dao Pharmaceutical Development Co., Ltd. held its 23rd meeting of the second board of directors on August 26, 2025, with all 9 directors present, ensuring compliance with legal and regulatory requirements [1] - The board approved several key proposals, including the review of the 2025 semi-annual report and the special report on the use of raised funds [2][3] - The board also approved the cancellation of the supervisory board and amendments to the company's articles of association, which will be submitted for shareholder approval [2][3] - The board nominated candidates for the third board of directors, including both non-independent and independent directors, pending shareholder approval [3][4] - The board reviewed and approved the semi-annual evaluation report of the 2025 quality improvement and efficiency recovery action plan [4] - The board discussed the 2025 restricted stock incentive plan and its management methods, which will also require shareholder approval [5][6] - The board proposed to authorize the board to handle matters related to the 2025 employee stock ownership plan, pending shareholder approval [8][9]

Meeting Overview - The second meeting of the Supervisory Board of Chengdu XianDao Pharmaceutical Development Co., Ltd. was held on August 26, 2025, with all three supervisors present [1] - The meeting was convened in accordance with relevant laws and regulations, and the resolutions passed were deemed legal and effective [1] Resolutions Passed - The Supervisory Board approved the company's 2025 semi-annual report and its summary [2] - The board also approved the special report on the storage and actual use of the raised funds for the first half of 2025 [2] - A resolution was passed to cancel the Supervisory Board, amend the company’s articles of association, and remove the chairman of the Supervisory Board, pending approval from the shareholders' meeting [2][3] - The board approved the draft of the 2025 restricted stock incentive plan and its summary, which will also be submitted for shareholder approval [3] - The implementation assessment management measures for the 2025 restricted stock incentive plan were approved, pending shareholder approval [3] - The verification of the list of incentive objects for the 2025 restricted stock incentive plan was also approved [3] - The draft of the 2025 employee stock ownership plan and its summary could not be resolved due to two supervisors abstaining from voting, and it will be submitted for shareholder approval [4] - The management measures for the 2025 employee stock ownership plan could not be resolved for the same reason and will also be submitted for shareholder approval [4]

Core Viewpoint - The Shenzhen BGI Genomics Co., Ltd. is holding its third extraordinary general meeting of shareholders in 2025 to discuss and vote on several key proposals, including amendments to the 2024 restricted stock incentive plan and the employee stock ownership plan, aimed at enhancing employee motivation and aligning interests with shareholders [5][22]. Group 1: Meeting Procedures - The meeting will ensure the legal rights of all shareholders and maintain order and efficiency, following relevant laws and regulations [1][2]. - Attendees must register and confirm their participation before the meeting starts, as latecomers will not be allowed to vote [2][3]. - The meeting will follow a predetermined agenda, allowing shareholders to exercise their rights to speak, inquire, and vote [2][3][4]. Group 2: Proposals and Amendments - Proposal One involves the revision of the 2024 restricted stock incentive plan, which aims to enhance performance assessment indicators at the company level [7][9]. - The revision is driven by the need to adapt to external market changes and to focus on increasing market share in the gene sequencing equipment sector, which is crucial for future revenue growth [9][10]. - Proposal Two addresses the amendments to the 2024 employee stock ownership plan, which also includes new performance assessment indicators to improve governance and employee engagement [16][17]. Group 3: Performance Assessment Criteria - The performance assessment for the incentive plans will be based on revenue growth rates, excluding impacts from public health events, with specific targets set for 2024 and 2025 [9][19]. - The revised criteria will include metrics related to gene sequencing equipment sales, emphasizing the importance of capturing market share to secure long-term customer value [10][18]. - The company aims to ensure that the revised performance targets remain challenging yet achievable, fostering a sustainable growth environment [20][21].

Investment Rating - The investment rating for the company is "Buy" [17] Core Views - The company achieved record high performance in Q2 2025, with revenue of 4.177 billion yuan, up 7.71% year-on-year, and a net profit of 313 million yuan, up 12.34% year-on-year [2][3] - The company is actively expanding its global presence, with overseas revenue growing by 27.21% year-on-year, contributing to 35.84% of total revenue [3] - The company has implemented an employee stock ownership plan to ensure stable growth, with performance targets set for net profit growth from 2025 to 2027 [4] Financial Performance - In H1 2025, the company reported revenue of 7.876 billion yuan, a year-on-year increase of 7.1%, and a net profit of 554 million yuan, up 11.42% year-on-year [2][3] - The gross profit margin for H1 2025 was 22.77%, with a net profit margin of 6.8% [4] - The company plans to distribute a cash dividend of 390 million yuan, representing 70.2% of its net profit for the period [4] Revenue Breakdown - Revenue from various product segments in H1 2025 included 5.461 billion yuan from paper packaging, 1.297 billion yuan from packaging accessories, 584 million yuan from eco-friendly paper-plastic products, and 379 million yuan from other products [3] - Domestic revenue decreased by 1.59% to 5.053 billion yuan, while overseas revenue increased by 27.21% to 2.823 billion yuan [3] Future Projections - Revenue projections for 2025 to 2027 are 19.129 billion yuan, 21.410 billion yuan, and 23.547 billion yuan, respectively, with year-on-year growth rates of 11%, 12%, and 10% [4] - Net profit projections for the same period are 1.637 billion yuan, 1.814 billion yuan, and 2.077 billion yuan, with year-on-year growth rates of 16%, 11%, and 14% [4]

Core Viewpoint - The company reported a revenue of 331 million yuan for the first half of 2025, with a net loss attributable to shareholders of 90.22 million yuan, although this loss is an improvement compared to the 93.30 million yuan loss in the same period last year [1] Group 1: Financial Performance - The company’s operating cash flow improved significantly, with a net cash flow of -77.62 million yuan, an improvement of over 220 million yuan compared to -304 million yuan in the same period last year [2] - The increase in cash flow was driven by a rise in collection amounts, with a 42 million yuan increase in cash receipts, and over 70% of the receivables from previous years being recovered [2] - The company has been facing challenges with accounts receivable, but improvements in customer structure and collection efforts are alleviating this issue [2] Group 2: Employee Stock Ownership Plan - The company launched an employee stock ownership plan aimed at directors, supervisors, executives, and key employees, with a total fundraising target of no more than 36.81 million yuan, corresponding to 1.034 million shares, which is about 1.81% of the total share capital [3] - The plan includes a lock-up period of up to 60 months and a performance assessment mechanism, with shares being unlocked in three phases based on the company's future performance targets [3][4] - The strict conditions of the plan are designed to align the interests of management and employees with the long-term value of the company, fostering a sense of responsibility and enhancing core competitiveness [4]

Core Viewpoint - Shanghai Zhezhong Group Co., Ltd. has completed the non-trading transfer of its first employee stock ownership plan, which involves the transfer of shares sourced from the company's repurchased stock [1][2][3] Group 1: Employee Stock Ownership Plan Details - The employee stock ownership plan was approved during the board meeting on July 18, 2025, and the first extraordinary shareholders' meeting on August 4, 2025 [1] - The plan aims to raise a maximum of 73.127125 million yuan, with each unit priced at 1 yuan, totaling 73,127,125 units [5][6] - A total of 100 individuals, including supervisors and core employees, participated in the plan, with the actual subscription amounting to 73,127,125 yuan [5][6] Group 2: Share Repurchase and Transfer - The company repurchased a total of 5,750,060 shares for 100.0076 million yuan from August 27, 2021, to August 31, 2022, and an additional 22,100,110 shares for approximately 241.477 million yuan from November 28, 2024, to August 2, 2025 [2][3] - The non-trading transfer of 5,850,170 shares to the employee stock ownership plan was completed on August 25, 2025, representing 1.32% of the company's total share capital, at a price of 12.50 yuan per share [6][7] Group 3: Governance and Accounting - The employee stock ownership plan does not have any related party relationships with the company's controlling shareholders or management, ensuring independence in decision-making [8] - The plan's duration is set for 60 months, with vesting periods at 12, 24, and 36 months based on performance assessments [7] - The company will follow the accounting standards for equity-settled share-based payments, with impacts on financial results to be confirmed by annual audit reports [9]

| 关于湖北久量股份有限公司 | | | | | | | --- | --- | --- | --- | --- | --- | | 终止第一期员工持股计划的 | | | | | | | 法律意见书 | | | | | | | 二〇二五年八月 | | | | | | | 广东君信经纶君厚律师事务所 | | | | | 法律意见书 | | 目 录 | | | | | | | 广东君信经纶君厚律师事务所 | | | | 法律意见书 | | | 释 | | 义 | | | | | 在本《法律意见书》中，下列简称仅具有如下特定含义： | | | | | | | 久量股份、本公司、公 | | | 湖北久量股份有限公司（原名称为"广东久量股份有限公 | | | | 指 | | | | | | | 司"） | 司 | | | | | | 中国证监会 中国证券监督管理委员会 | 指 | | | | | | 《公司法》 《中华人民共和国公司法》 | 指 | | | | | | 《证券法》 《中华人民共和国证券法》 | 指 | | | | | | 《关于上市公司实施员工持股计划试点的指导意见》（中国 | | | | | | | ...